Trusted Resource for Clinical Trials, Protocols & Progress
While Good Clinical Practice (GCP) guidelines and regulatory frameworks such as USFDA and ICH E6 define SAE documentation and timelines, the underlying principle is the protection of human subjects. Ethics plays a pivotal role in ensuring that:
Click to read the full article.
In safety monitoring, noise refers to AE patterns or statistical anomalies that mimic potential safety signals but lack consistency, biological plausibility, or clinical relevance. Noise can arise due to:
Click to read the full article.
According to USFDA and ICH E2E guidelines, a safety signal is defined as “information arising from one or multiple sources (including observations and experiments) which suggests a new potentially causal association, or a new aspect of a known association, between an intervention and an event or set of related events.”
Click to read the full article.
Signal validation is the systematic evaluation of a potential safety signal to confirm its accuracy, relevance, and clinical significance. According to EMA guidelines and ICH E2E, a signal becomes validated when there is sufficient evidence to support a causal association or a new aspect of a known association between the drug and the adverse event.
Click to read the full article.
AE clusters refer to patterns of adverse events that occur more frequently than expected within a certain time frame, population subgroup, or treatment group. Identifying these clusters can help highlight emerging safety concerns before they escalate.
Click to read the full article.
Aggregate data review involves evaluating cumulative safety information collected from all subjects in a clinical trial—or across multiple trials involving the same investigational product. This includes a consolidated analysis of adverse events (AEs), serious adverse events (SAEs), lab values, vital signs, and other clinical outcomes to detect potential safety signals.
Click to read the full article.
